University Medical Center Groningen
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1614-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- https://www.umcg.nl
Clinical Trials
923
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (451 trials with phase data)• Click on a phase to view related trials
Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection
- Conditions
- Esophageal CarcinomaGastric Carcinoma
- Interventions
- Drug: Indocyanine Green (IC-Green)Diagnostic Test: Fluorescence guided identification using indocyanine green
- First Posted Date
- 2025-08-07
- Last Posted Date
- 2025-08-07
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 10
- Registration Number
- NCT07108855
- Locations
- 🇳🇱
University Medical Centre Groningen, Groningen, Netherlands
Smart Blister Packaging and Mobile Application to Monitor and Support Medication Adherence: a Two-arm Usability Study
- Conditions
- Healthy Volunteer Study
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 36
- Registration Number
- NCT07099612
- Locations
- 🇳🇱
University Medical Center Groningen (UMCG), Groningen, Netherlands
The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
- Conditions
- Prostate Cancer (Adenocarcinoma)OligoProgressive Metastatic DiseaseCastration Resistant Metastatic Prostate CancerRadiotherapy
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 35
- Registration Number
- NCT07038304
- Locations
- 🇳🇱
UMC Groningen, Groningen, Netherlands
🇳🇱Radboud Umc, Nijmegen, Netherlands
The Added Value of Three-dimensional Electroanatomic Mapping For Accurate Delivery Of Pulsed Field Ablation In The Pulmonary Veins Compared To Pulsed Field Ablation With Fluoroscopy And/Or Intracardiac Echocardiography Alone In The Treatment Of Atrial Fibrillation: MAP-PFA Study
- Conditions
- Atrial Fibrillation (AF)
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 32
- Registration Number
- NCT07014423
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Netherlands
Fluid Management and Individualized Resuscitation in Sepsis
- Conditions
- SepsisCritical Care, Fluid ResuscitationFluid ResponsivenessShockPersonalized MedicineEmergency Medicine
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 174
- Registration Number
- NCT07009665
- Locations
- 🇳🇱
University Medical Centre Groningen, Groningen, Netherlands
- Prev
- 1
- 2
- 3
- 4
- 5
- 117
- Next
News
Team Sports Enhance Cognitive Development and Academic Success in Children, Studies Show
Children participating in team sports like soccer and volleyball demonstrate superior executive function skills compared to those in individual sports or no sports, according to a Dutch longitudinal study published in JAMA Network Open.
Tirzepatide Shows Promising Renal Benefits in Type 2 Diabetes Patients Through SURPASS Trials Analysis
Post hoc analysis of SURPASS trials reveals tirzepatide significantly reduced urine albumin-to-creatinine ratio by up to 26.3% compared to control groups in type 2 diabetes patients.
Brexu-Cel Demonstrates High Response Rates in BTK Inhibitor-Naive Relapsed/Refractory MCL
Brexucabtagene autoleucel (brexu-cel) shows a 91% overall response rate (ORR) in patients with relapsed/refractory mantle cell lymphoma (MCL) who are BTK inhibitor-naive.
Ozempic Shows Promise in Curbing Kidney Disease in Obese Individuals Without Diabetes
Semaglutide, the active agent in Ozempic and Wegovy, demonstrates a significant 52% reduction in kidney damage among obese individuals without diabetes.
ASN Kidney Week 2024: Novel Clinical Trials Highlight Advances in Kidney Disease Treatment
Finerenone shows similar long-term kidney function patterns to placebo in heart failure patients, while reducing protein leakage, suggesting potential benefits in specific outcomes.